Cereno Scientific announces appointment of Dr. Raymond L. Benza to the Scientific Advisory Board
Cereno Scientific today announced that Dr. Raymond L. Benza, M.D., FACC, FAHA, FACP, USA, has joined the company’s Scientific Advisory Board (SAB). Dr. Benza is a global thought leader within pulmonary arterial hypertension (PAH) and has been working as an advisor to the company’s Phase II program with drug candidate CS1 in PAH.Dr. Benza, M.D., FACC, FAHA, FACP, USA, comments, “Cereno Scientific’s CS1 has tremendous potential to be a game-changer for patients with PAH. I am pleased to have advised the company during 2020 and now look forward to joining the company’s SAB. These patients do